Central serotonergic descending pain pathway (CSDPP)

The central serotonergic descending pain pathway is a fundamental component of the endogenous pain modulation system, originating primarily in the nucleus raphe magnus and other nuclei within the rostroventromedial medulla (RVM) (Millan, 2002). This pathway projects to the dorsal horn of the spinal cord, where it releases serotonin (5-HT) to modulate the transmission of nociceptive signals from primary afferent fibers to second-order neurons (Ossipov et al., 2010). The pathway is characterized by its bidirectional nature, meaning it can either inhibit or facilitate pain depending on the specific serotonin receptor subtypes activated; for example, 5-HT1A and 5-HT7 receptors generally mediate antinociception, while 5-HT2A and 5-HT3 receptors are often associated with pro-nociceptive facilitation (Bannister & Dickenson, 2016). Dysregulation of this system, particularly a shift toward facilitation or a loss of inhibition, is a hallmark of chronic pain conditions such as fibromyalgia and neuropathic pain. Pharmacological agents like serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants target this pathway by increasing synaptic serotonin levels to reinforce descending inhibitory control (Marks et al., 2009). Understanding this pathway is crucial for developing therapies that can selectively enhance endogenous analgesia while minimizing side effects like serotonin syndrome.

Other names

Descending serotonergic systemRaphe-spinal serotonergic pathwayDescending inhibitory pain pathwayBulbospinal serotonergic pathway

Enhancement of descending inhibitory control by increasing serotonin availability in the spinal dorsal horn, leading to the activation of inhibitory receptors (e.g., 5-HT1A, 5-HT7) and suppression of nociceptive transmission.